
Sign up to save your podcasts
Or


GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have opened doors for people to lose weight. Should everyone have the option to take it? Those arguing “yes” say obesity needs to be treated using every available tool, especially for people for whom diet, lifestyle changes, and exercise aren’t enough. Those arguing “no” are concerned about its side effects and the risks if people don’t take them as directed. Now we debate: should prescription weight loss drugs be available for all?
Arguing Yes: David Allison, Obesity Researcher; Dean and Distinguished Professor at the Indiana University School of Public Health-Bloomington
Arguing No: Stuart W. Flint, Associate Professor of the Psychology of Obesity at the University of Leeds
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices
By Open to Debate4.6
21102,110 ratings
GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have opened doors for people to lose weight. Should everyone have the option to take it? Those arguing “yes” say obesity needs to be treated using every available tool, especially for people for whom diet, lifestyle changes, and exercise aren’t enough. Those arguing “no” are concerned about its side effects and the risks if people don’t take them as directed. Now we debate: should prescription weight loss drugs be available for all?
Arguing Yes: David Allison, Obesity Researcher; Dean and Distinguished Professor at the Indiana University School of Public Health-Bloomington
Arguing No: Stuart W. Flint, Associate Professor of the Psychology of Obesity at the University of Leeds
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices

32,054 Listeners

38,475 Listeners

6,793 Listeners

30,726 Listeners

25,802 Listeners

8,769 Listeners

9,200 Listeners

3,982 Listeners

5,095 Listeners

776 Listeners

111,848 Listeners

7,222 Listeners

16,373 Listeners

15,849 Listeners

617 Listeners